A phase 1/1b study of PUR1900 an inhaled formulation of itraconazole in healthy volunteers and asthmatics to study safety tolerability and pharmacokinetics

摘要

Oral itraconazole has variable pharmacokinetics and risks of adverse events associated with high plasma exposure. An inhalation formulation of itraconazole (PUR1900) is being developed to treat allergic bronchopulmonary aspergillosis, an allergic inflammatory disease occurring in asthmatics and patients with cystic fibrosis.